Drugs / Cannabidiol (CBD)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07167446 | Oct 2025 → Sep 2027 expected | chemotherapy-induced neuropathy, colorectal cancer | Fox Chase Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cannabidiol (CBD) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07167446 ↗ |
| Known as | hemp-derived cannabidiol | “hemp-derived cannabidiol” NCT07167446 ↗ |
| Route | Oral | “Oral hemp-derived CBD capsules” NCT07167446 ↗ |